Clover Health Investments Corp Stock Price, News & Analysis

Clover Health (NASDAQ:CLOV) has appointed Joseph Oldakowski as Vice President of Finance and Controller, reporting to CFO Peter Kuipers. Oldakowski brings nearly 20 years of healthcare and insurance finance experience, most recently serving as VP and Corporate Controller at Point32Health.

In his new role, Oldakowski will lead Clover's corporate accounting, GAAP, SEC, and statutory financial reporting and tax functions. His prior experience includes leadership positions at EmblemHealth, The Hartford, and MassMutual, along with public accounting experience at Melanson Heath specializing in healthcare audits.

The appointment strengthens Clover's financial leadership as the company focuses on scaling operations and driving profitable growth in its Medicare-focused healthcare business.

Clover Health (Nasdaq: CLOV) has announced a strategic partnership with IPC Digital Health to launch a new community pharmacy pilot program across New Jersey. The initiative leverages IPC's iCare+ Independent Pharmacy Network to help Medicare Advantage members better manage their medications and improve health outcomes.

The program integrates real-time monitoring tools powered by Clover Assistant data and AI models to track prescription fills, identify adherence gaps, and facilitate collaboration between local pharmacists, doctors, and Clover's care teams. This community-based approach aims to enhance medication management while keeping healthcare services local and personalized for seniors.

Clover Health (NASDAQ:CLOV) has scheduled its Second Quarter 2025 earnings release and conference call for August 5, 2025. The financial results will be released after market close, followed by a conference call and webcast at 5:00 p.m. Eastern Time.

Investors can access the conference call by dialing 800-245-3047 (U.S.) or 203-518-9765 (international) with conference ID CLOVQ225. A live and archived webcast will be available on the company's investor relations website for 12 months.

Clover Health (NASDAQ:CLOV) announced its upcoming inclusion in the broad-market Russell 3000® Index, effective June 30, 2025. This inclusion automatically grants the company membership in either the large-cap Russell 1000® Index or small-cap Russell 2000® Index, along with corresponding growth and value style indexes.

The Russell indexes reconstitution process captures the 4,000 largest US stocks based on total market capitalization as of April 30, 2025. According to FTSE Russell data, approximately $10.6 trillion in assets are benchmarked against Russell's US indexes as of June 2024.

Clover Health (NASDAQ: CLOV) reported strong Q1 2025 results with significant improvements across key metrics. The company's Medicare Advantage membership grew 30% year-over-year to 103,418 members, while total revenues increased 33% to $462 million. Profitability metrics showed remarkable improvement, with GAAP net loss narrowing to $1 million from $19 million year-over-year, and Adjusted EBITDA rising 279% to $26 million. The company's Clover Assistant technology demonstrated strong performance, with data showing 18% lower hospitalizations and 25% lower 30-day readmissions for Congestive Heart Failure patients. Based on these results, Clover Health improved its full-year 2025 guidance, projecting Medicare Advantage membership growth of 30% and insurance revenue between $1.8-1.875 billion, representing 37% growth year-over-year at the midpoint.

Clover Health (NASDAQ: CLOV) subsidiary Counterpart Health released research showing positive outcomes associated with their AI-powered Counterpart Assistant (CA) technology in treating congestive heart failure patients. The study revealed that patients whose Primary Care Physicians use CA experienced 18% lower hospitalization rates and 25% lower 30-day readmission rates.

The technology provides actionable insights at point of care, supporting earlier disease detection and guideline-based treatment. Patients with CA-using physicians showed higher rates of outpatient cardiologist visits and in-home care management. This marks Counterpart's fourth retrospective analysis, following previous studies on Diabetes, Chronic Kidney Disease, and Medication Adherence.

Clover Health (Nasdaq: CLOV) announced significant changes to its Board of Directors. Lee A. Shapiro, current Chairman of the Audit Committee and Nominating and Corporate Governance Committee, will not seek re-election at the 2025 Annual Shareholders' Meeting, concluding his four-year tenure on June 10, 2025.

Shapiro's departure is due to his upcoming role as Chairman of the American Heart Association. Thomas L. Tran, a current Audit Committee member, will succeed Shapiro as Chairman of both the Audit Committee and the Nominating and Corporate Governance Committee effective June 10, 2025.

Both CEO Andrew Toy and Executive Chairperson Vivek Garipalli expressed gratitude for Shapiro's contributions and leadership during his tenure, while Tran committed to maintaining high standards of financial integrity and transparency in his new role.

Clover Health (Nasdaq: CLOV) has announced its participation in two major upcoming investor conferences in May 2025. Chief Financial Officer Peter Kuipers will lead the company's presence at these events:

• A presentation at the 2025 Bank of America Healthcare Conference on May 14, 2025, at 6:00 p.m. Eastern Time, which will be available via live webcast and replay on Clover's investor relations website
• Participation in the 22nd Annual Craig-Hallum Institutional Investor Conference on May 28, 2025

Clover Health (Nasdaq: CLOV) has scheduled its First Quarter 2025 earnings release for Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day to discuss the quarterly business and financial results.

Investors and interested parties can access the earnings call by dialing 800-274-8461 (U.S. callers) or 203-518-9814 (international callers) using the conference ID: CLOVQ125. A live webcast will be available through the Investor Relations section of Clover Health's website, with the recording remaining accessible for 12 months.